PPT-Lêsfeardigens nivo’s

binnen en tusken teksten Reitze Jonkman Lektoraat Frysk amp Meartaligens Kolleezje 13 juny 2017 Twa leardoelen fan dit kolleezje Oan de ein kensto. eventsof. . nivolumab. and . docetaxel. in the . CheckMate. 017 and . CheckMate. 057 phase III NSCLC trials. . Kartik. . Venkatachalam. Intervista a Cesare . Gridelli. Background: Nivo, a PD-1 antibody, received FDA approval based on superior overall survival in metastatic squamous (SQ) and non-squamous (NSQ) NSCLC patients who have progressed on or after platinum-based doublet chemotherapy. The purpose of this study was to assess the frequency and associated costs of grade 2–4 AEs in the CheckMate 017 (SQ) and CheckMate 057 (NSQ) phase III pivotal trials of nivo vs doc in stage IIIB/IV NSCLC. Methods: Patient-level data from these two trials were utilized to estimate the frequency of TRAEs requiring management in the nivo and doc arms, including serious and non-serious TRAEs. Minimum follow-up for AE reporting at database lock was 12 months. Grade 3–4 AE costs by event were identified from Healthcare Cost and Utilization Project (HCUP) data in 2010, which were adjusted to reflect 2012-equivalent US costs. Healthcare utilization associated with grade 2 AEs was based on clinical opinion and costs were based on HCUP or other sources as appropriate. Results: In both trials, more TRAEs were observed with doc than with nivo (Table), and the cost of managing TRAEs was 15.8 and 10.7 times higher in the doc arm vs the nivo arm for the CheckMate 017 and CheckMate 057 trials, respectively. Patients in the doc arm incurred an additional $6,585 and $5,422 per patient in managing AEs compared with patients in the nivo arm in the above two trials, respectively. The total estimated costs of managing TRAEs during these trials are presented in the Table. Conclusions: Large estimated differences in costs were observed in managing TRAEs, favoring nivo in the CheckMate 017 and CheckMate 057 pivotal trials. The reduction in costs for managing AEs with the use of nivo should be considered when assessing the value of nivo in this patient population.. High-Risk and Metastatic Melanoma. Timothy M. Kuzel, MD. Professor of Medicine and Dermatology. Feinberg School of Medicine. Northwestern University. Chicago. ICLIO 1. st. Annual National Conference. Milton Barros e Silva,. 1. Rafael Schmerling,. 2 . Andreia. Cristina de Melo,. 3. Sergio Azevedo,. 4. Bernardo Garicochea,. 5. Elaine McWhirter,. 6. Michael Smylie,. 7. Markus Gifoni,. 8. Carlos Henrique dos Anjos,. Cancer. Perspectives From the 2015 Oncology . Meeting. Targeted . Therapy for Metastatic Melanoma . Keith T. Flaherty, . MD . Associate Professor, Department of . Medicine . Harvard . Medical School. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Emerging role of immune checkpoint inhibitors and other novel strategies in MPM. Associate Professor Philip Beale. Chair ANZGOG Clinical Trials Group. Medical Oncologist Sydney. Concord Hospital. Chris O’Brien Lifehouse. Royal Prince Alfred Hospital. Outline. Background to immunotherapy. Associate Professor Philip Beale. Chair ANZGOG Clinical Trials Group. Medical Oncologist Sydney. Concord Hospital. Chris O’Brien Lifehouse. Royal Prince Alfred Hospital. Outline. Background to immunotherapy. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Effectiveness and role of . immunotherapy in patients with tumor driver mutations . NAN KLIMA YO (CLIMATE READY BOSTON). DEFI PREPARASYON POU CHANJMAN NAN KLIMA. ENPAK YO LA A. LI LÈ POU N PREPARE NOU.. OBJEKTIF PWOGRAM LIDÈ KLIMATIK CRB. . Konprann enpak yo pi byen. . Ankouraje manm kominote yo pou pwogrese nan estrateji rezistans yo. the Time-resolved Fluorescence technology is optional therefore double check if the reader is equipped with TR-FRET module Two sequential measurements should be carried out at 620 nm for the cryptate BackgroundBackground continuedStudy DesignClinical ActivityConclusionsPIVOT-02 STUDY SCHEMAImmunotherapy agents in combination with chemotherapy have altered the course of metastatic triple-negative b Clinical Research Treatment . Flowchart. First Line, . Resectable. First Line, Metastatic or unresectable without previous CPI. First Line, Stage 3. Neoadjuvant + Adjuvant. Melanoma. . Trials. SWOG 2015. vs . Platinum-Doublet Chemotherapy . as First-line Treatment for . Advanced . Non-Small . Cell Lung . Cancer: Initial . Results . From . CheckMate 227. Matthew D. Hellmann,. 1. . Tudor-. Eliade. . Ciuleanu,.